Skip to main content
Equibles
BBIO logo

BBIO · BridgeBio Pharma, Inc. · Metrics

Track BBIO — free

Use BBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$72.50 -3.58 (-4.71%) At close · Sep 10
Russell 1000 member Rebalance outlook locked
Market Cap
$14.72B
Shares
195.49M

BBIO metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$72.50
Market cap
$14.72B

Price action

20 metrics
Price change (1W)
-0.5%
Price change (30D)
-9.1%
Price change (3M)
+12.9%
Price change (6M)
+6.6%
Price change (YTD)
-0.5%
Price change (1Y)
+42.2%
Trailing year
Price change (5Y)
+49.6%
52-week high
$90.17
52-week low
$49.00
Change from 52-week high
-15.6%
Change from 52-week low
+55.3%
Annualized volatility
46.6%
Annualized volatility (3M)
41.5%
Beta
1.1
RSI (14D)
39.0
Price vs SMA 50
-5.8%
Price vs SMA 200
+2.9%
Avg volume (3M)
3.03M
Relative volume
0.8
Average dollar volume
$236.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
195.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
20.6×
reciprocal yield 4.8%
P / book
—
FCF yield
-3.0%
TTM · current market cap
Buyback yield
1.4%
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
30.3×
reciprocal yield 3.3%
EV / revenue historical average (5Y)
30.3×
reciprocal yield 3.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
94.4%
Operating margin
-69.8%
Trailing 12 months
Net margin
-98.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$497.80M
Net income (TTM)
−$702.02M
Trailing 12 months
Diluted EPS (TTM)
$-3.57
FCF margin
-61.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-10.71

Growth

11 metrics
Revenue growth YoY
+120.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$713.07M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.8%
Year over year · more shares
Revenue CAGR (3Y)
+86.3%
Revenue CAGR (5Y)
+127.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-57.7%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$492.72M
Free cash flow (TTM)
−$435.39M
Quick ratio
1.2
Interest coverage
-10.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$677.91M
Total assets
$1.22B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$434.37M
Capital expenditures (TTM)
$1.01M
R&D (TTM)
$505.38M
SG&A (TTM)
$645.86M
Stock compensation (TTM)
$147.22M
R&D / revenue
70.9%
Stock compensation / revenue
20.6%

Ownership (13F)

3 metrics
13F filers
479
13F filer change QoQ
+12
Institutional ownership
105.6%

Short interest

3 metrics
Short interest
11.2%
Latest settlement · 11.2 days to cover
Days to cover
11.2d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$27.59M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1743881 CUSIP 10806X102 13F (30d) 257 filings 253 filers Visit website Investor relations